Successful treatment of refractory anemia by high-dose methylprednisolone associated with an increment in CD68-positive cells in bone marrow

American Journal of Hematology

Volumn 66, Issue 2, 2001, Pages 80-84

  Motomura, Sayuri ^a   Motoji, Toshiko ^a   Okutomi, Keiko ^a   Nishikawa, Toshio ^a   Kasajima, Takeshi ^a   Mizoguchi, Hideaki ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

CD68; Macrophage; Methylprednisolone; Monocyte; Myelodysplastic syndrome; Refractory anemia

Indexed keywords

CD68 ANTIGEN; METHYLPREDNISOLONE;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; CANCER RISK; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REFRACTORY ANEMIA; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA, REFRACTORY; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOLOGICAL MARKERS; BONE MARROW CELLS; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0035142118     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-8652(200102)66:2<80::AID-AJH1021>3.0.CO;2-U     Document Type: Article

References (23)

1. The myelodysplastic syndromes
2. Treatment of the myelodysplastic syndromes: An updated Japanese experience
3. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes
4. Differentiation therapy
5. Treatment of myelodysplastic syndromes with all-trans-retinoic acid
6. Evaluation of low dose ARA-C versus supportive care in the treatment of myelodysplastic syndromes: An intergroup study by the Eastern Cooperative Oncology Group and the Southwest Oncolgy Group
7. Treatment of myelodysplastic syndromes with orally administrated 1-β-Darabinofuranosylcytosine-5′-stearylphosphate
8. Successful treatment of refractory anemia with highdose methylprednisolone
9. Proposals for the classification of the myelodysplastic syndromes
10. Immunohistochemical demonstration of keratins in human ovarian neoplasms
11. Antithymocyte globulin for patients with myelodysplastic syndrome
12. International scoring system for evaluating prognosis in myelodysplastic syndromes
13. Immunemediated complications in patients with myelodysplastic syndromesclinical and cytogenetic features
14. Immunological abnormalities in myelodysplastic syndromes
15. Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients
16. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome
17. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow
18. Down-regulation of myelopoiesis by mediators inhibiting the production of macrophage-derived granulomonopoietic enhancing activity (GM-EA)
19. Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes
20. Measurement of serum cytokine levels in patients with myelodysplastic syndromes
21. Novel insights into the biology of myelodysplastic syndromes: Excessive apoptosis and the role of cytokines
22. Effect of recombinant human tumor necrosis factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor cells
23. Serum TNF-α, γ-INF, G-CSF and GM-CSF levels in neutropenic children with acute leukemia treated with short-course, highdose methylprednisolone